Regulation and function of the p53-related proteins: Same family, different rules

Trends in Cell Biology

Volumn 10, Issue 5, 2000, Pages 197-202

  Lohrum, Marion A E ^a   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; UNCLASSIFIED DRUG;

CANCER INHIBITION; CARCINOGENESIS; CELL DIVISION; DEVELOPMENT; ONCOGENE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0034192628     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(00)01736-0     Document Type: Review

References (60)

1. Greenblatt M.S.et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
2. Attardi L.D., Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell. Mol. Life Sci. 55:1999;48-63.
3. Chen X. The p53 family: same response, different signals? Mol. Med. Today. 5:1999;387-392.
4. Kaelin W.G. Jr. The p53 gene family. Oncogene. 18:1999;7701-7705.
5. White E., Prives C. DNA damage enables p73. Nature. 399:1999;734-737.
6. Yang A.et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 398:1999;714-717.
7. Mills A.A.et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 398:1999;708-713.
8. Celli J.et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell. 99:1999;143-153.
9. Takada N.et al. Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Res. 59:1999;2810-2814.
10. Zeng X.et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19:1999;3257-3266.
11. Zhu J.et al. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273:1998;13030-13036.
12. Bates S., Vousden K.H. Mechanisms of p53-mediated apoptosis. Cell. Mol. Life Sci. 55:1999;28-37.
13. Ozaki T.et al. Deletion of the COOH-terminal region of p73α enhances both its transactivation and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res. 59:1999;5902-5907.
14. Venot C.et al. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17:1998;4668-4679.
15. Zhu J.et al. Differential regulation of cellular target genes devoid of the PXXP motifs with impaired apoptotic function. Oncogene. 18:1999;2149-2155.
16. Chi S-W.et al. Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 18:1999;4438-4445.
17. Roth J., Dobbelstein M. Failure of viral oncoproteins to target the p53-homologue p51A. J. Gen. Virol. 80:1999;3251-3255.
18. Yang A.et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 3:1998;305-316.
19. Di Como C.J.et al. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1999;1438-1449.
20. Davison T.S.et al. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J. Biol. Chem. 274:1999;18709-18714.
21. Matleshewski G. p53: twenty years on, meeting review. Oncogene. 18:1999;7618-7620.
22. Kubbutat M.H.G., Vousden K.H. Keeping an old friend under control: regulation of p53 stability. Mol. Med. Today. 4:1998;250-256.
23. Oren M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274:1999;36031-36034.
24. Ashcroft M., Vousden K.H. Regulation of p53 stability. Oncogene. 18:1999;7637-7643.
25. Lozano G., Montes de Oca Luna R. MDM2 function. Biochim. Biophys. Acta. 1377:1998;M55-M59.
26. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
27. Fang S.et al. Ubiquitin protein ligase activity of Mdm2: differential RING finger requirements for ubiquitination and proteasomal targeting of mdm2 and p53. J. Biol. Chem. 275:2000;8945-8951.
28. Gostissa M.et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18:1999;6462-6471.
29. Rodriguez M.S.et al. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18:1999;6455-6461.
30. Grossman S.R.et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell. 2:1998;405-415.
31. Thomas A., White E. Suppression of the p300-dependent mdm2 negative-feedback loop induced the p53 apoptotic function. Genes Dev. 12:1998;1975-1985.
32. Yuan Z.M.et al. Role for p300 in stabilization of p53 in the response to DNA damage. J. Biol. Chem. 274:1999;1883-1886.
33. Kubbutat M.H.G.et al. Regulation of Mdm2 directed degradation by the C-terminus of p53. Mol. Cell. Biol. 18:1998;5690-5698.
34. Lee C-W., La Thangue N.B. Promotor specificity and stability control of the p53-related protein p73. Oncogene. 18:1999;4171-4181.
35. Mayo L.D.et al. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57:1997;5013-5016.
36. Khosravi R.et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DMA damage. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14973-14977.
37. Zaika A.et al. Cytoplasmically 'sequestered' wild-type p53 protein is resistant to Mdm2-mediated degradation. J. Biol. Chem. 274:1999;27474-27480.
38. Damalas A.et al. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18:1999;3054-3063.
39. An W.G.et al. Stabilization of wild-type by hypoxia-inducible factor 1α Nature. 392:1998;405-408.
40. Shvarts A.et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15:1996;5349-5357.
41. Jackson M.W., Berberich S.J. MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20:2000;1001-1007.
42. Sharp D.A.et al. Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein. J. Biol. Chem. 274:1999;38189-38196.
43. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
44. Roussel M.F. The INK4 family of cell-cycle inhibitors in cancer. Oncogene. 18:1999;5311-5317.
45. Palmero I., Peters G. Perturbation of cell-cycle regulators in human cancer. Cancer Surv. 27:1996;351-367.
46. Eischen C.M.et al. Disruption of the ARF-Mdm2-p53 tumor-suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:1999;2658-2669.
47. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6937-6941.
48. Weber J.D.et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1:1999;20-26.
49. Lohrum M.A.E.et al. Identification of a cryptic nucleolar localization signal in MDM2. Nat. Cell Biol. 2:2000;179-181.
50. Ongkeko W.M.et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr. Biol. 9:1999;829-832.
51. Harrington E.A.et al. Oncogenes and cell death. Curr. Opin. Genet. Dev. 4:1994;120-129.
52. Weinberg R.A. E2F and cell proliferation: a world turned upside down. Cell. 85:1996;457-459.
53. Vigo E.et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell. Biol. 19:1999;6379-6395.
54. Nevins J.R. Towards an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 9:1998;585-593.
55. ARF links the tumour suppressors RB and p53. Nature. 395:1998;124-125.
56. Ding Y.et al. Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. DNA Res. 6:1999;347-351.
57. Phillips A.C.et al. E2F-1 potentiates cell death by blocking anti-apoptotic signaling pathways. Mol. Cell. 4:1999;771-781.
58. Yang A.et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 404:2000;99-103.
59. Lohrum M.A.E.et al. Contribution of two independent MDM2 binding domains in p14ARF to p53 stabilization. Curr. Biol. 2000;. (in press).
60. Weber J.D.et al. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20:2000;2517-2528.